Differential inhibition of neuronal and extraneuronal monoamine oxidase

Neuropsychopharmacology

Volumn 15, Issue 3, 1996, Pages 296-301

  Eisenhofer, Graeme ^a   Lenders, Jacques W M ^b   Harvey White, Judith ^a   Ernst, Monique ^a   Zametkin, Alan ^a   Murphy, Dennis L ^a   Kopin, Irwin J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Catecholamines; Metabolism; Monoamine oxidase; Monoamine oxidase inhibitors; Norepinephrine; Normetanephrine

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; AMINE OXIDASE (FLAVIN CONTAINING); DEBRISOQUINE; SELEGILINE;

ARTICLE; NERVE CELL; PRIORITY JOURNAL;

EID: 0030248638     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00233-4     Document Type: Article

References (26)

1. Berlin I, Zimmer R, Thiede H-M, Payan C, Hergueta T, Robin L, Puech AJ (1990): Comparison of the monoamine oxidase inhibiting properties of two selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effects on psychometric performance in healthy subjects. Br J Clin Pharmacol 30:805-816
2. Berry MD, Juorio AV, Paterson IA (1994a): The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog Neurobiol 42:375-391
3. Berry MD, Juorio AV, Paterson IA (1994b): Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol 44:141-161
4. Brunner HG, Nelen MR, van Zandvoort P, Abeling NGGM, van Gennip AH, Wolters EC, Kuiper MA, Ropers HH, van Oost BA (1993): X-linked borderline mental retardation with prominent behavioural disturbance: Phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am J Hum Genet 52:1032-1039.
5. Caramona MM, Osswald W (1985): Effects of clorgyline and (-)-deprenyl on the deamination of normetanephrine and noradrenaline in strips and homogenates of the canine saphenous vein. Naunyn-Schmiedeberg's Arch Pharmacol 328:396-400
6. Devor EJ, Cloninger CR, Hoffman PL, Tabakoff B (1993): Association of monoamine oxidase (MAO) activity with alcoholism and alcoholic subtypes. Am J Med Genet 48:209-213
7. Eisenhofer G, Finberg JPM (1994): Different metabolism of norepinephrine and epinephrine by catechol-O-methyl-transferase and monoamine oxidase in rats. J Pharmacol Exp Ther 268:1242-1251
8. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ (1986): Simultaneous liquid-Chromatographic determination of 3,4-dihydroxy-phenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 32:2030-2033
9. Eisenhofer G, Goldstein DS, Ropchak TG, Kopin IJ (1988): Source and physiological significance of plasma 3,4-dihydroxyphenylalanine in the rat. J Neurochem 51: 1204-1213
10. Eisenhofer G, Friberg P, Pacak K, Goldstein DS, Murphy DL, Tsigos C, Quyyumi AA, Brunner HG, Lender JWM (1995): Plasma metadrenalines: Do they provide useful information about sympatho-adrenal function and catecholamine metabolism. Clin Sci 88:533-542
11. Gershon ES, Targun SD, Leckman JF (1979): Platelet monoamine oxidase (MAO) activity and genetic vulnerability to bipolar (BP) affective illness. Psychopharmacol Bull 15:27-30
12. Giachetti A, Shore PA (1967): Monoamine oxidase inhibition in the adrenergic neuron by bretylium, debrisoquin, and other adrenergic blocking agents. Biochem Pharmacol 16:237-238
13. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ (1988): Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest 81:213-220
14. Graefe K-H, Henseling M (1983): Neuronal and extraneuronal uptake and metabolism of catecholamines. Gen Pharmacol 14:27-33
15. Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, Zimmer RH (1989): Inhibition of monoamine oxidase by moclobemide: Effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Pharmacol 27:243-255
16. Lai JCK, Leung TKC, Lim L (1994): Heterogeneity of monoamine oxidase activities in synaptic and non-synaptic mitochondria derived from three brain regions: Some functional implications. Metab Brain Dis 9:53-66
17. Lavian G, Finberg JP, Youdim MB (1994): Comparison of the effect of reversible and irreversible MAO inhibitors on renal nerve activity in the anesthetized rat. J Neural Transm 41:107-113
18. Lenders JWM, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin IJ (1993): Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 39:97-103
19. Lenders JWM, Eisenhofer G, Abeling NGGM, Berger W, Murphy DL, Konings H, Bleeker Wagemakers LM, Kopin IJ, Karoum F, van Gennip AH, Brunner HG (1996): Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest (in press)
20. Linnoila M, Karoum F, Potter WZ (1982): Effect of low low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. Arch Gen Psychiatry 39:513-516
21. Medina MA, Giachetti A, Shore PA (1969): On the physiological disposition and possible mechanism of the antihypertensive action of debrisoquin. Biochem Pharmacol 18:891-901
22. Murphy DL, Garrick NA, Cohen RM (1980): Monoamine oxidase inhibitors and monoamine oxidase: Biochemical and physiological aspects relevant to human psychopharmacology. In Burrows GD, Norman TR, Davies B (eds), Antidepressants. Amsterdam, Elsevier, pp. 209-227
23. Pettinger WA, Korn A, Spiegel H, Pocelinko R, Abrams WB (1969): Debrisoquin, a selective inhibitor of intraneuronal monoamine oxidase in man. J Pharmacol Ther 10:667-674
24. Silas JH, Jones J, Tucker GT, Townshend MM, Phillips CA, Smith AJ (1979): Dissociation of biochemical and hypotensive effects of debrisoquine in hypertensive patients. Eur J Clin Pharmacol 16:81-86
25. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985): Tyramine precursor sensitivity changes during deprenyl treatment. Psychopharmacology 86:432-437
26. Thorpe LW, Westlund KN, Kochersperger LM, Abell CW, Denney RM (1987): Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. J Histochem Cytochem 35:23-32